Clarivate Epidemiology's coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of male LUTS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of male LUTS for each…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key BPH patient populations covering 171 countries and more than 99% of…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from…
The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s…
Clarivate Epidemiology’s coverage of giant cell arteritis (GCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…